🇺🇸 FDA
Patent

US 10889637

Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies

granted A61KA61K2039/505A61K39/395

Quick answer

US patent 10889637 (Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies) held by The Board of Regents of the University of Texas System expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K39/395, A61P, A61P19/10